CHEBI:145372 - gilteritinib

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name gilteritinib
ChEBI ID CHEBI:145372
Definition A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C29H44N8O3
Net Charge 0
Average Mass 552.724
Monoisotopic Mass 552.35364
InChI InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
InChIKey GYQYAJJFPNQOOW-UHFFFAOYSA-N
SMILES CCC1=NC(C(=O)N)=C(NC2=CC=C(N3CCC(CC3)N4CCN(C)CC4)C(OC)=C2)N=C1NC5CCOCC5
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): apoptosis inducer
Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1).
Application(s): antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing gilteritinib (CHEBI:145372) has role antineoplastic agent (CHEBI:35610)
gilteritinib (CHEBI:145372) has role apoptosis inducer (CHEBI:68495)
gilteritinib (CHEBI:145372) has role EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor (CHEBI:62434)
gilteritinib (CHEBI:145372) is a N-methylpiperazine (CHEBI:46920)
gilteritinib (CHEBI:145372) is a aromatic amine (CHEBI:33860)
gilteritinib (CHEBI:145372) is a monomethoxybenzene (CHEBI:25235)
gilteritinib (CHEBI:145372) is a oxanes (CHEBI:46942)
gilteritinib (CHEBI:145372) is a piperidines (CHEBI:26151)
gilteritinib (CHEBI:145372) is a primary carboxamide (CHEBI:140324)
gilteritinib (CHEBI:145372) is a pyrazines (CHEBI:38314)
gilteritinib (CHEBI:145372) is a secondary amino compound (CHEBI:50995)
IUPAC Name
6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide
INNs Sources
gilteritinib WHO MedNet
giltéritinib WHO MedNet
gilteritinib WHO MedNet
gilteritinibum WHO MedNet
Synonyms Sources
6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide ChemIDplus
6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide IUPAC
ASP 2215 ChemIDplus
ASP-2215 DrugBank
ASP2215 DrugBank
Brand Name Source
Xospata ChEBI
Manual Xrefs Databases
D10709 KEGG DRUG
DB12141 DrugBank
Gilteritinib Wikipedia
View more database links
Registry Number Type Source
1254053-43-4 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
26279055 PubMed citation Europe PMC
27908881 PubMed citation Europe PMC
28516360 PubMed citation Europe PMC
28645776 PubMed citation Europe PMC
29498296 PubMed citation Europe PMC
30039554 PubMed citation Europe PMC
30514344 PubMed citation Europe PMC
30721452 PubMed citation Europe PMC
30936061 PubMed citation Europe PMC
31069015 PubMed citation Europe PMC
31122910 PubMed citation Europe PMC
31203997 PubMed citation Europe PMC
31320594 PubMed citation Europe PMC
31454267 PubMed citation Europe PMC
31469903 PubMed citation Europe PMC
31528345 PubMed citation Europe PMC
31665578 PubMed citation Europe PMC
31692922 PubMed citation Europe PMC
PMC6817455 PubMed Central citation Europe PMC
Last Modified
14 November 2019